share_log

TCR2 Therapeutics(TCRR.US)股东增持5万股普通股股份,价值约为8.6万美元

Shareholders of TCR2 Therapeutics (TCRR.US) increased their common stock holdings by 50,000 shares, worth about US$86,000

Futu News ·  May 31, 2023 08:40

It was reported on May 31 that according to the documents disclosed by the US Securities and Exchange Commission (SEC) on May 30,$TCR2 Therapeutics (TCRR.US)$Shareholder TANG KEVIN C increased his holdings of common stock by 50,000 shares at an average price of 1.72 US dollars per share on May 25, worth about 86,000 US dollars.

The transaction involved other related parties: TANG CAPITAL MANAGEMENT LLC and TANG CAPITAL PARTNERS LP.

1685492827227249293.png

What is a statement of change in shareholding?

The SEC requires insiders of listed companies to publicly disclose their securities transactions and shareholding. When an insider's shareholding changes, depending on different circumstances, it is necessary to submit a statement of change in shareholding to the SEC within a certain period of time after the transaction is completed.

Insiders include the company's directors and executives, as well as any shareholder who owns 10% or more of the company's tradable shares.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment